Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $973.13 Consensus Price Target from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given an average recommendation of “Moderate Buy” by the twenty-five analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, sixteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $966.88.

Several research firms recently commented on REGN. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $634.23 on Friday. The firm has a 50 day moving average of $682.93 and a 200-day moving average of $791.84. The company has a market cap of $69.34 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $618.51 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $11.86 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $28,000. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares in the last quarter. Finally, Avalon Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $36,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.